<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies suggest that blockade of angiotensin type 1 (AT1) receptor may have some effect on <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>Serum level of preheparin <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase (LPL) reflects LPL production mainly in adipocytes and is believed to be related to insulin sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the effect of a selective AT1 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, <z:chebi fb="0" ids="9927">valsartan</z:chebi>, on <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism and the preheparin LPL mass in 55 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were randomized into a group administered <z:chebi fb="0" ids="9927">valsartan</z:chebi> 80 mg/day for 12 weeks or a group not administered <z:chebi fb="0" ids="9927">valsartan</z:chebi> (control) </plain></SENT>
<SENT sid="4" pm="."><plain>Blood pressure decreased significantly </plain></SENT>
<SENT sid="5" pm="."><plain>HbA1c and TG levels decreased and <z:chebi fb="0" ids="47775">HDL-C</z:chebi> level increased, but these changes tended to be significantly different </plain></SENT>
<SENT sid="6" pm="."><plain>TC and <z:chebi fb="0" ids="47774">LDL-C</z:chebi> levels were not significant changes </plain></SENT>
<SENT sid="7" pm="."><plain>Preheparin LPL mass increased after <z:chebi fb="0" ids="9927">valsartan</z:chebi> administration compared with control (P = 0.0307), and migration ratio of <z:chebi fb="15" ids="39026">LDL</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>-Rm), which correlated negatively with <z:chebi fb="15" ids="39026">LDL</z:chebi> particle size, decreased compared with control (P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>DeltaLDL-Rm correlated inversely with Delta preheparin LPL mass (r = -0.459) </plain></SENT>
<SENT sid="9" pm="."><plain>Among subjects treated with <z:chebi fb="0" ids="9927">valsartan</z:chebi>, greater improvement in preheparin LPL mass and blood pressure was observed in the subgroup with preheparin LPL mass &lt;40 ng/ml </plain></SENT>
<SENT sid="10" pm="."><plain>The results of this study suggest that <z:chebi fb="0" ids="9927">valsartan</z:chebi> may enhance LPL production in adipocytes, resulting in enlarged <z:chebi fb="15" ids="39026">LDL</z:chebi> particle size </plain></SENT>
</text></document>